Dihexa

Dihexa is a synthetic, orally active peptidomimetic derived from the angiotensin IV analog Norleucine-1-angiotensin IV. It was developed by Joseph Harding and colleagues at Washington State University in the early 2010s, with foundational research published around 2011–2013. It belongs to a class sometimes described as 'nootropic peptides' or angiotensin-derived cognitive compounds, and it is notable among peptide researchers for being reported as orally bioavailable — a relatively rare property in this compound class. Dihexa is not approved for human use by the FDA, MHRA, EMA, or TGA, and is sold strictly as a research chemical. This content is for educational purposes only and does not constitute medical advice.

The proposed mechanism of action centers on HGF/MET signaling. Animal research from Washington State University, published in the Journal of Pharmacology and Experimental Therapeutics (2013), suggests Dihexa binds to HGF with high affinity and potentiates its activity at the MET receptor — a receptor tyrosine kinase implicated in neurogenesis, synaptic plasticity, and cell survival. The research team proposed this mechanism results in synaptogenesis, the formation of new synaptic connections, which may underlie observed improvements in spatial memory tasks in rodent models. The compound was reported in those early studies to be orders of magnitude more potent than BDNF in terms of synaptogenic activity in vitro, a claim that generated significant attention in nootropic research communities but has not been independently validated in human trials.

The evidence base for Dihexa is almost entirely preclinical. The foundational animal studies (Benoist et al., 2011; McCoy et al., 2013) used rodent models of scopolamine-induced and age-related cognitive impairment and reported statistically significant improvements in Morris water maze performance. These are animal studies — the translational relevance to human cognition is unknown. There are no published randomized controlled trials in humans, no Phase I/II safety trials in the public domain, and no peer-reviewed human pharmacokinetic data. Anecdotal self-reports circulate in biohacker and nootropics communities (Reddit, Longecity forums) describing subjective improvements in verbal fluency, working memory, and motivation, with some reports also describing irritability, emotional blunting, or anxiety. These anecdotal reports carry no clinical weight and should be interpreted as hypothesis-generating at best. The absence of human safety data is a material concern that distinguishes Dihexa from more-studied peptides in this category.

Dosing ranges reported in the preclinical literature vary. Oral dosing in rodent models has been reported at approximately 1 mg/kg, with some protocols using lower doses transdermally. Extrapolating animal milligram-per-kilogram doses to human equivalents using standard allometric scaling is methodologically unreliable and not supported by human pharmacokinetic data. Anecdotal human self-reports in online communities describe oral doses ranging from 2 mg to 15 mg, and transdermal application using DMSO or similar carriers has also been self-reported. These figures come from uncontrolled, unverified self-experimentation — they are not dosing recommendations, and Peptide Guides does not recommend any dose for human use. Any dosing information here is reported strictly from research contexts and user-reported sources for educational purposes only.

Legal status: In the United States, Dihexa is not scheduled under the Controlled Substances Act and exists in a regulatory gray area as an unscheduled research chemical — it is not approved for human use but is not explicitly prohibited for research purposes. Similar unregulated research-chemical status applies in the UK and most EU jurisdictions. In Australia, novel research chemicals may fall under scheduling provisions depending on interpretation; prospective researchers should consult current TGA scheduling before importing. Sourcing due diligence is critical given the absence of a regulated supply chain: purchasers should require a certificate of analysis (COA) from an accredited third-party laboratory confirming identity (HPLC), purity (>98% preferred), and absence of heavy metal contaminants. Lyophilized powder should be stored frozen and away from UV light; reconstituted solutions (if applicable) should be refrigerated and used promptly. Vendors who do not provide COAs on request should be considered disqualifying.